bpc-157 adverse events case report human Doctors are using a regulatory gap to prescribe an unauthorized peptide FDA Committee Votes to Ease

(2014) Molecular Medicine , 20(1): 658666 Phase 2 clinical study confirming ARA-290 (4 mg daily 28 days) improved HbA1c, lipid profiles, and neuropathic symptoms in type 2 diabetes patients over 56 days

The majority of these peptides currently exist in a gray zone where they are legal to purchase and own but are not approved for human use

Treatment recommendations are based on provider evaluation

It is supplied as a research material and is not authorised, approved, or intended for human or veterinary use, clinical application, diagnostic procedures, or therapeutic purposes

Patients receiving the peptide showed meaningful reductions in their Small Fiber Neuropathy Screening List scores compared to placebo